| First Author | Roszko KL | Year | 2017 |
| Journal | JCI Insight | Volume | 2 |
| Issue | 3 | Pages | e91079 |
| PubMed ID | 28194446 | Mgi Jnum | J:280180 |
| Mgi Id | MGI:6369201 | Doi | 10.1172/jci.insight.91079 |
| Citation | Roszko KL, et al. (2017) Knockin mouse with mutant Galpha11 mimics human inherited hypocalcemia and is rescued by pharmacologic inhibitors. JCI Insight 2(3):e91079 |
| abstractText | Heterotrimeric G proteins play critical roles in transducing extracellular signals generated by 7-transmembrane domain receptors. Somatic gain-of-function mutations in G protein alpha subunits are associated with a variety of diseases. Recently, we identified gain-of-function mutations in Galpha11 in patients with autosomal-dominant hypocalcemia type 2 (ADH2), an inherited disorder of hypocalcemia, low parathyroid hormone (PTH), and hyperphosphatemia. We have generated knockin mice harboring the point mutation GNA11 c.C178T (p.Arg60Cys) identified in ADH2 patients. The mutant mice faithfully replicated human ADH2. They also exhibited low bone mineral density and increased skin pigmentation. Treatment with NPS 2143, a negative allosteric modulator of the calcium-sensing receptor (CASR), increased PTH and calcium concentrations in WT and mutant mice, suggesting that the gain-of-function effect of GNA11(R6OC) is partly dependent on coupling to the CASR. Treatment with the Galpha11/q-specific inhibitor YM-254890 increased blood calcium in heterozygous but not in homozygous GNA11(R60C) mice, consistent with published crystal structure data showing that Arg60 forms a critical contact with YM-254890. This animal model of ADH2 provides insights into molecular mechanism of this G protein-related disease and potential paths toward new lines of therapy. |
